Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents. 2015

Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
School of Medicine, China Medical University, Taichung 404, Taiwan.

Hepatitis B virus (HBV) is a causative reagent that frequently causes progressive liver diseases, leading to the development of acute, chronic hepatitis, cirrhosis, and eventually hepatocellular carcinoma (HCC). Despite several antiviral drugs including interferon-α and nucleotide derivatives are approved for clinical treatment for HBV, critical issues remain unresolved, e.g., low-to-moderate efficacy, adverse side effects, and resistant strains. In this study, novel Paeonol-phenylsulfonyl derivatives were synthesized and their antiviral effect against HBV was evaluated. The experimental results indicated that these compounds process significant antiviral potential, including the inhibition of viral antigen expression and secretion, and the suppression of HBV viral DNA replication. Among compounds synthesized in this research, compound 2-acetyl-5-methoxyphenyl 4-methoxybenzenesulfonate (7f) had the most potent inhibitory activity with IC50 value of 0.36 μM, and high selectivity index, SI (TC50/IC50) 47.75; which exhibited an apparent inhibition effect on viral gene expression and viral propagation in cell culture model. So, we believe our compounds could serve as reservoir for antiviral drug development.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000098 Acetophenones Derivatives of the simplest aromatic ketone acetophenone (of general formula C6H5C(O)CH3).
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
January 2024, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
January 2023, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
January 2016, Molecules (Basel, Switzerland),
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
July 2023, Natural product research,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
December 2020, RSC advances,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
June 2020, Bioorganic & medicinal chemistry,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
March 2022, European journal of medicinal chemistry,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
June 2017, Molecules (Basel, Switzerland),
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
May 2024, Chemistry & biodiversity,
Tsurng-Juhn Huang, and Hong Chuang, and Yu-Chuan Liang, and Hui-Hsien Lin, and Jia-Cherng Horng, and Yu-Cheng Kuo, and Chia-Wen Chen, and Fu-Yuan Tsai, and Shih-Chieh Yen, and Shih-Ching Chou, and Ming-Hua Hsu
July 2018, MedChemComm,
Copied contents to your clipboard!